Bulk Inquiry
Vandetanib
- ZD 6474
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C22H24BrFN4O2
- MW: 475.35
Description
Vandetanib (ZD6474) is an orally active multikinase inhibitor targeting VEGFR2, EGFR and RET receptor tyrosine kinases.
Vandetanib combines anti-angiogenic VEGFR2 inhibition with blockade of EGFR- and RET-driven tumor signaling. It is a clinically established reference for RET-dependent thyroid cancer and multikinase pathway studies.
Key Features
- VEGFR2, EGFR and RET tyrosine kinase inhibitor
- Combines anti-angiogenic and antiproliferative mechanisms
- Orally active multikinase pharmacology
- Clinically validated RET-targeted agent
Applications
- RET kinase and mutation studies
- VEGFR2 angiogenesis assays
- EGFR signaling research
- Thyroid cancer and multikinase resistance models
More Information
| Parent CAS No. | 443913-73-3 |
|---|---|
| Chemical Name | (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine |
| SMILES | N1(C)CCC(COC2C=C3N=CN=C(NC4C(F)=CC(Br)=CC=4)C3=CC=2OC)CC1 |
| MFCD | MFCD07772346 |
| InChi | InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) |
| InChiKey | UHTHHESEBZOYNR-UHFFFAOYSA-N |
| CID | 3081361 |
| Short Description | VEGFR/EGFR inhibitor |
References
- RS Herbst et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs. 2007, 16, 239-249.
- SR Wedge et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
- D. Vitagliano et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer. 2010 Nov 30;18(1):1-11.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
